The Sidney Kimmel Comprehensive Cancer Center
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Clinical Trials
572
Active:38
Completed:307
Trial Phases
5 Phases
Early Phase 1:23
Phase 1:168
Phase 2:226
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (515 trials with phase data)• Click on a phase to view related trials
Phase 2
226 (43.9%)Phase 1
168 (32.6%)Not Applicable
92 (17.9%)Early Phase 1
23 (4.5%)Phase 3
6 (1.2%)Physician- and Patient-based Barriers to NGS Testing
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Prostate Cancer
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-06
- Target Recruit Count
- 256
- Registration Number
- NCT07209176
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Not Applicable
Not yet recruiting
- Conditions
- Head and Neck CancerSquamous Cell CarcinomaOral Cavity CancerOropharyngeal CancerLaryngeal CancerSinonasal Squamous Cell CarcinomaHPV (Human Papillomavirus)-Associated CarcinomaSkull Base TumorsHPV 16 Positive Oropharyngeal Tumors (OPC)
- Interventions
- First Posted Date
- 2025-10-06
- Last Posted Date
- 2025-10-23
- Target Recruit Count
- 75
- Registration Number
- NCT07209189
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-09-26
- Target Recruit Count
- 60
- Registration Number
- NCT07142551
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
DK222 Study at Hopkins
Not Applicable
Not yet recruiting
- Conditions
- Non-Small Cell Lung CancerUrothelial Cancer
- Interventions
- Drug: [18F]DK222 radiotracer
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-10-28
- Target Recruit Count
- 6
- Registration Number
- NCT07140315
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Pediatric Radiation Therapy Registry
Recruiting
- Conditions
- SarcomaPediatric Brain Tumors
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-11-05
- Target Recruit Count
- 5000
- Registration Number
- NCT07129317
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 114
- Next
News
Breakthrough Study Reveals Hidden Cancer Cells in 42% of Ovarian Cancer Patients in Clinical Remission
A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy.